Fluorescent nanosensors for detection of intracellular singlet oxygen during plasma therapy

Author(s):  
Peuli Nath ◽  
Raoul Kopelman ◽  
John Foster ◽  
Jacques Amar ◽  
Aniruddha Ray
The Analyst ◽  
2021 ◽  
Author(s):  
Peuli Nath ◽  
Sameer Sayel Hamadna ◽  
Leshern Karamchand ◽  
John Foster ◽  
Raoul Kopelman ◽  
...  

Detection of singlet oxygen is of great importance for a range of therapeutic applications, particularly photodynamic therapy, plasma therapy and also during photoendosomolytic activity. Here we present a simple method...


1998 ◽  
Vol 67 (4) ◽  
pp. 399 ◽  
Author(s):  
Lydia J. Martínez ◽  
Robert H. Sik ◽  
Colin F. Chignell
Keyword(s):  

1999 ◽  
Author(s):  
Philip B. Keating ◽  
Michael F. Hinds ◽  
Steven J. Davis

2020 ◽  
Author(s):  
busenur Aslanoglu ◽  
Ilya Yakavets ◽  
Vladimir Zorin ◽  
Henri-Pierre Lassalle ◽  
Francesca Ingrosso ◽  
...  

Computational tools have been used to study the photophysical and photochemical features of photosensitizers in photodynamic therapy (PDT) –a minimally invasive, less aggressive alternative for cancer treatment. PDT is mainly based by the activation of molecular oxygen through the action of a photoexcited sensitizer (photosensitizer). Temoporfin, widely known as mTHPC, is a second-generation photosensitizer, which produces the cytotoxic singlet oxygen when irradiated with visible light and hence destroys tumor cells. However, the bioavailability of the mostly hydrophobic photosensitizer, and hence its incorporation into the cells, is fundamental to achieve the desired effect on malignant tissues by PDT. In this study, we focus on the optical properties of the temoporfin chromophore in different environments –in <i>vacuo</i>, in solution, encapsulated in drug delivery agents, namely cyclodextrin, and interacting with a lipid bilayer.


2020 ◽  
Vol 11 (SPL1) ◽  
pp. 546-549
Author(s):  
Shweta Dadarao Parwe ◽  
Milind Abhimanyu Nisargandha ◽  
Rishikesh Thakre

Hitherto, there is no proper line of treatment for the new (nCOVID19). The development of unique antiviral drugs has taken precedence. Therapeutic antibodies () will be a significantly beneficial agent against nCOVID-19. Here the host immune responses to new discussed in this review provide strategy and further treatment and understanding of clinical interventions against nCOVID-19. Plasma therapy uses the antibodies found in the blood of people recovering (or convalesced) from an infection to treat infected patients. When an infection occurs, the body begins producing proteins specially made to kill the germ, called antibodies. Those antibodies coat specifically plasma in the blood of survivors, the yellow transparent liquid blood portion for months or even years. research assesses plasma use from Convalescent patients of infected with nCOVID-19 as a possible preventive treatment. But it is not yet recommended as a line of treatment, and it is used as a clinical trial in the new in Indian population.


2000 ◽  
Vol 12 (1/2) ◽  
pp. 136-137
Author(s):  
Shigeki MUTO ◽  
Yosuke KOBAYASHI ◽  
Yoshinobu TAKEKAWA ◽  
Masamori ENDO ◽  
Kenzo NANRI ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document